Abbott Laboratories (ABT) 42.23 $ABT
LABS, Inc. Names Todd G. Johnson as President and Chief Executive Officer
Business Wire - Tue Sep 02, 2:57PM CDT
LABS, Inc., a Centennial-based comprehensive, highly accredited specialized clinical reference testing laboratory, announced it has appointed Todd G. Johnson, MBA, as President and Chief Executive Officer. Based at LABS, Inc. Centennial headquarters, Johnson's initial priorities will be to continue to grow the company, and ensure that the organization remains competitive within the market place.
Next Support Level for Abbott Laboratories (ABT) is $41.89
Comtex SmarTrend(R) - Tue Sep 02, 12:28PM CDT
Shares of Abbott Laboratories (NYSE:ABT) opened today below their pivot of $42.24 and have already reached the first level of support at $42.06. Analysts will be watching for a cross of the next downside pivot targets of $41.89 and $41.54.
Fitch Maintains CFR's IDRs on Rating Watch Positive
Business Wire - Fri Aug 29, 12:47PM CDT
Fitch Ratings maintains CFR Pharmaceuticals S.A. and its subsidiary CFR International SpA on Rating Watch Positive in anticipation of their acquisition by Abbott Investments Luxembourg S.A.R.L., a subsidiary of Abbott Laboratories (Abbott; rated 'A+' by Fitch). A complete list of rating actions follows at the end of this press release.
Drug Discovery Technologies - A Global Market Overview
M2 - Fri Aug 29, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dtdx3f/drug_discovery) has announced the addition of the "Drug Discovery Technologies - A Global Market Overview" report to their offering. The development of new drugs for treating difficult diseases, such as cancer requires extensive expenditure, in addition to consuming a lot of time. The first step in designing a new drug involves the utilizing high-throughput screening of large chemical libraries for identifying compounds that can provide the requisite therapeutic effect. The capability of visualizing biological activity at the cellular level has constituted a strategic component in drug discovery, and adding automation and high-volume screening methods has enabled in testing compounds in large numbers. The field of pharmaceutical research is being provided considerable impetus through the combination of imaging and screening. Key Topics Covered: PART A: GLOBAL MARKET PERSPECTIVE 1. INTRODUCTION 2. KEY MARKET TRENDS 3. RECENT PATENTS IN DRUG DISCOVERY LANDSCAPE 4. KEY GLOBAL PLAYERS 5. KEY BUSINESS TRENDS 6. GLOBAL MARKET OVERVIEW PART B: REGIONAL MARKET PERSPECTIVE 1. THE UNITED STATES 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART C: GUIDE TO THE INDUSTRY 1. NORTH AMERICA 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART
ANNEXURE 1. RESEARCH METHOLOGY 2. FEEDBACK Companies Mentioned: - 4-Antibody AG - Abbott Laboratories - Accelrys, Inc. - Affymetrix Inc. - Agilent Technologies Inc. - Asahi Kasei Pharma Corporation - Astrazeneca Plc - Aviva Biosciences Corp. - Bayer Healthcare AG - BD Biosciences - Beckman Coulter Inc. - Biacore International AB - Bioanalytical Systems, Inc. - Bio-Rad Laboratories, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Caliper Life Sciences, Inc. - Caprion Proteomics, Inc. - Celera Corporation - Celgene Corporation - Charles River Laboratories International, Inc. - Compugen Ltd. - Decode Genetics, Inc. - EMD Millipore Corporation - Evotec AG - GE Healthcare Ltd. - Genedata AG - Hitgen Ltd - Hudson Robotics, Inc. - Illumina Inc. - Incyte Corporation - Isis Pharmaceuticals, Inc. - Kyowa Hakko Kirin Co., Ltd. - Luminex Corporation - Maxcyte, Inc - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Molecular Devices, LLC - Molecular Discovery Ltd. - Molecular Discovery Systems Pty., Ltd. - New England Biolabs, Inc. - Novartis AG - Osiris Therapeutics Inc. - Perkinelmer, Inc. - Promega Corporation - Qiagen N.V. - Quantum Pharmaceuticals - Roche Holding AG - Shimadzu Corporation - Sigma-Aldrich Corporation - Sri Biosciences - Tecan Group Ltd. - The National Center for Drug Screening - Thermo Fisher Scientific Inc. - Viva Biotech Ltd - Waters Corp. For more information visit http://www.researchandmarkets.com/research/dt..._discovery
Global Infant Formula Market Report: Focus on China 2014
M2 - Thu Aug 28, 9:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/twqn7f/global_infant) has announced the addition of the "Global Infant Formula Market Report: Focus on China" report to their offering. The market for infant formula products is one of the major and the fastest growing segments of the overall baby foods industry. Infant formula is either a partial or a total substitute for breast milk for infants and is recommended for feeding during the first twelve months. Since the start of the millennium, international awareness regarding the importance of early childhood nutrition has been on the rise. All over the world parents are becoming more concerned about the nutritional benefit of pediatric foods and breast-milk supplements. Increasing proportion of women participation in labor force and increased affordability supported by waning price responsiveness and a rise in disposable income across the world are the major factors that have helped the global IMF market to attain stronger growth levels. Though the market has been experiencing lower demand and growth from the traditional matured markets of the West stemming primarily from declining birth rate, the developing world, especially the Asia and Pacific region and Latin America have provided the headroom for the global market expansion. The market is dominated by the Asian region which consumes about three-fifths of the global IMF supplies. Particularly, China has gained the stature to maneuver the market single-handedly since the country alone accounts for about two-fifth of the global IMF market revenues. The report, Global Infant Formula Market prudently analyzes the development of the respective market, with a focus on the single largest market, China, and other regional but important markets. The report discusses the major trends, growth drivers as well as issues being faced by the industry. The global infant formula market is predominated by a handful of players including Nestl?, Danone, Mead Johnson Nutrition and Abbott which keep vying for greater market share. The profiles of these leading players are also included in the report along with their key financials and strategies for growth. . Key Topics Covered: 1. Market Overview 2. Baby Food/Infant Nutrition Market 3. Market Dynamics 4. Competitive Landscape 5. Company Profiles 6. Market Outlook Companies Mentioned - Abbott Laboratories - Danone S.A. - Mead Johnson Nutrition Co. - Nestl? S.A. For more information visit http://www.researchandmarkets.com/research/tw...bal_infant
Frustrating Boston Scientific Is Not What the Investor Ordered
at The Street - Thu Aug 28, 5:30AM CDT
It will only take one bad quarter for shares to fall to single digits. That's the only time you should buy.
Abbott Laboratories Has Returned 10.4% Since SmarTrend Recommendation (ABT)
Comtex SmarTrend(R) - Wed Aug 27, 10:05AM CDT
SmarTrend identified an Uptrend for Abbott Laboratories (NYSE:ABT) on April 22nd, 2014 at $38.75. In approximately 4 months, Abbott Laboratories has returned 10.39% as of today's recent price of $42.77.
Home Healthcare Global Market Report - Forecast to 2020 for the $300 Million Industry
M2 - Wed Aug 27, 8:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lbsmjs/home_healthcare) has announced the addition of the "Home Healthcare Global Market - Forecast to 2020" report to their offering. Global home healthcare market is expected to reach more than $300 billion by 2019 growing at a CAGR of around 8.0% from 2014 to 2019 The home healthcare equipment market is expected to grow at a faster rate compared to home healthcare services market. Home healthcare is gaining a tremendous attention over hospitals for the sophistication, ease and privacy of treatment it offers. Increased in-hospital care cost, comfort of recovering at home and enhanced age-related chronic diseases in developing as well as developed countries are factors driving the overall growth of home healthcare market. Whereas factors such as poor technology adoption, weak reimbursement policies and rapidly changing technologies are hampering the market growth. Moreover, high capital costs, medical equipment, human resources and conventional model of business are the challenges faced by home healthcare market. The opportunities increasing the market trend is attributed to medical insurance by governments or organizations and cost-effectiveness.North America adopting novel technologies and portable diagnostic devices accounts for the largest share in the home healthcare market. While Europe with the presence of well-equipped healthcare reimbursement structure is the second leading market. Asia-Pacific is expected to grow at the highest CAGR driven by the aging population in countries such as India, China, and Japan. Key Topics Covered: 1. Executive Summary 2. Introduction 3. Market Analysis 4. Home Healthcare Therapeutic Equipment Market 5. Home Healthcare Services Market 6. Home Healthcare Telehealth Market 7. Regional Market Analysis 8. Company Developments 9. Major Company Profiles - Abbott Laboratories - Baxter International - Braun - Novo Nordisk - GE Healthcare - Invacare - Johnson and Johnson - Medtronic - Philips Healthcare - Roche Holding AG For more information visit http://www.researchandmarkets.com/research/lb...healthcare
Microfluidic Device System Market 2013 - 2019
M2 - Wed Aug 27, 3:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x345bg/microfluidic) has announced the addition of the "Microfluidic Device System Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. The global microfluidic device market was valued at USD 1,531.2 million in 2013. It is likely to grow at a CAGR of 22.8% during 2013 to 2019 to reach USD 5,246.4 million in 2019. Microfluidics is an evolving scientific field with numerous analytical applications and commercial potential. Globally, the microfluidic device market is witnessing significant growth due to increasing R&D investment in pharmaceuticals, life science and rising point of care testing demand. New trends in healthcare, such as healthcare at home, supports point of care testing (POCT) as the most efficient and effective delivery of healthcare. It has many applications in other areas such as drug screening, sugar testers, chemical micro reactor, microprocessor cooling and micro fuel cells. Rising demand for point of care testing, miniaturization of chip, and increasing demand for microfluidic devices in genomics and proteomics are the key growth drivers for the microfluidic device market. In addition, change in material mix would provide opportunity for new market entrants, which would further drive the growth of the microfluidic device market. North America was valued at USD 644.5 million in 2013 and is expected to reach USD 2,095.5 million in 2019, growing at a CAGR of 21.7% from 2013 to 2019. In-vitro diagnostics microfluidic device market was valued at USD 949.6 million in 2013 and is expected to reach USD 3,317.4 million in 2019, growing at a CAGR of 23.2% from 2013 to 2019. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Industry Analysis Chapter 4 Market Trends Chapter 5 Porters Five Force Analysis Chapter 6 Global Market Size and Forecast Chapter 7 Segment Analysis - by Material Chapter 8 Segment Analysis - by Industry Chapter 9 Segment Analysis - by Application Chapter 10 Regional Analysis Chapter 11 Competitive Landscape Chapter 12 Company Profiles - Abbott Laboratories - Agilent Technologies Inc - Becton, Dickinson and Company - Bio- Rad Laboratories - Cepheid - Dolomite Centre - Fluidigm Corporation - Johnson & Johnson - Micronit Microfluidics - RainDance Technologies - Roche Diagnostics - Siemens Healthcare For more information visit http://www.researchandmarkets.com/research/x3...crofluidic
Abbott Laboratories (ABT) Breaks Through Resistance at $42.70
Comtex SmarTrend(R) - Tue Aug 26, 10:41AM CDT
Shares of Abbott Laboratories (NYSE:ABT) have bullishly opened above the pivot of $42.49 today and have reached the first resistance level of $42.70. Should the shares continue to rise, the resistance pivots of $42.92 and $43.35 will be of interest.
Collaborations, New Contract, Dividend Declaration, and Capacity Expansion - Research Reports on Abbott, CB&I, Weyerhaeuser, Cardinal Health and SolarCity
PR Newswire - Tue Aug 26, 7:50AM CDT
Today, Analysts Review released its research reports regarding Abbott Laboratories (NYSE: ABT), Chicago Bridge & Iron Company N.V. (NYSE: CBI), Weyerhaeuser Co. (NYSE: WY), Cardinal Health, Inc. (NYSE: CAH) and SolarCity Corporation (NASDAQ: SCTY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5978-100free.
North American Interventional Cardiology & Peripheral Vascular Devices (Angioplasty Balloon, Stent, Catheter, IVC Filter, Endovascular Stent Graft) Market Report
M2 - Tue Aug 26, 3:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pxpdkk/north_american) has announced the addition of the "North American Interventional Cardiology & Peripheral Vascular Devices Market by Angioplasty Balloon, Stent, Catheter, IVC Filter, Endovascular Stent Graft - Forecast to 2018" report to their offering. The North American interventional cardiology and peripheral vascular devices market is expected to grow at a CAGR of 2.9% from 2013 to 2018. Both, the lower volume of coronary angioplasty procedures and the increasing prevalence rate of peripheral artery diseases have impacted the market significantly. Amongst all the product segments, bioabsorbable stents, retrievable inferior vena cava filters, and diagnostic catheters (intravascular ultrasound and optical coherence tomography catheters) markets are identified as the high growth segments in the North American interventional cardiology and peripheral vascular devices market. Better diagnosis of thrombus using IVUS and OCT catheters is expected to drive the diagnostic catheters market; whereas, lesser risk of long-term post surgical complications in DVT/PE treatments will encourage faster adoption of the retrievable inferior vena cava filters in the coming years. The bioabsorbable stents are still not available for clinical usage in the U.S. However, bioabsorbable stents are available on a special access basis by Health Canada. The usage factors of different surgical instruments were the major hindrances while deriving the market size of the corresponding surgical devices. This is primarily due to the availability of various surgical instruments for the treatment of similar cardiac ailments. For instance, coronary angioplasty can be performed through plain balloon catheter, stent, and/or a combination of stent and catheter, based on patients' cardiac health. The study on the North American interventional cardiology and peripheral vascular devices market captures an exhaustive list of surgical devices which are used in various types of angioplasty procedures, deep vein thrombosis, endovascular aneurysm repairing, and chronic total occlusion (CTO) treatment procedures. This research illustrates specific driving and restraining factors in the U.S. and Canadian markets; furthermore, it identifies the high-growth regions with regard to the interventional cardiology and peripheral vascular devices market. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Premium Insights 4 Market Overview 5 Angioplasty Balloons 6 Angioplasty Stents 7 Catheters Market 8 Endovascular Aneurysm Repair (EVAR) Stent Grafts Market 9 Inferior Vena Cava (IVC) Filters Market 10 Plaque Modification Devices Market 11 Hemodynamic Flow Alteration Devices Market 12 Accessory Devices Market 13 Geographic Analysis 14 Competitive Landscape 15 Company Profiles - Abbott Laboratories - Biotronik SE & Co. Kg - Boston Scientific Corporation - B. Braun Melsungen AG - Cook Medical, Inc. - Cordis Corporation - Covidien Plc - C. R. Bard, Inc. - Medtronic Inc. - W.L.Gore & Associates, Inc. For more information visit http://www.researchandmarkets.com/research/px...h_american
Nitinol Medical Devices Market Forecasts & Opportunities, 2019 - Semi-finished Raw Material & Final Medical Components Analysis
M2 - Tue Aug 26, 3:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w8xqrs/nitinol_medical) has announced the addition of the "Nitinol Medical Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. The total market of nitinol medical devices for final medical components was valued at USD 8,287.2 million in 2012 and is forecasted to grow at a CAGR of 11.1% during the period of 2013 to 2019. Based on the type of final medical components, the total market is subdivided into nitinol stents, guidewires and others, which comprises dental wires, catheter tubes, tissue ablators, needles, retrieval baskets, biopsy forceps, endodontic files and filters. Among these afore-mentioned components, nitinol stents market accounted for the largest market share in 2012 and is expected to retain its market share till 2019 due to increasing number of vascular stenting procedures globally. Additionally, growing medical device manufacturer's preference for using nitinol as a chief raw material owing to its unique biomechanical properties is further expected to drive the market for nitinol stents in coming years. Based on the type of semi-finished raw materials, the market is categorized into nitinol tubes, wiring and others, which comprise sheets and ribbons. The total market for nitinol semi-finished raw materials was valued at USD 1,525.2 million in 2012. Of these, the Nitinol-wiring market accounted for the largest market share in 2012. The contributing factors for such an assessment included a large number of clinical applications, low cost and better corrosion resistance properties compared to tubes and others. Nitinol wires are currently being deployed in various applications such as orthopedics, endoscopy, laparoscopy, catheter wall supports, ablation catheter, custom springs, etc. Geographically, North America constituted the largest market for global nitinol medical devices market in 2012; however, Asia-Pacific is predicted to foresee the fastest growth rate during the forecast period from 2013 to 2019. This high growth has been attributed to presence of large population base which consequently gives rise to large patient population, low treatment cost and increasing healthcare awareness among the patients. In addition, favorable government support and growing medical tourism industry would trigger the growth of this market in Asia-Pacific. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Nitinol Medical Devices Market, by Semi-finished Raw Material Chapter 5 Global Nitinol Medical Devices Market, by Final Medical Components Chapter 6 Global Nitinol Medical Devices Market, by Geography Chapter 7 Recommendations Chapter 8 Company Profiles - Abbott Laboratories, Inc. - Boston Scientific Corporation - Cook Medical, Inc. - Covidien plc - C. R. Bard, Inc. - Custom Wire Technologies, Inc. - ENDOSMART GmbH - Medtronic, Inc. - Nitinol Devices & Components, Inc. - Terumo Corporation For more information visit http://www.researchandmarkets.com/research/w8...ol_medical
MedTech Defies Sequestration, M&As Steal the Show - Industry Outlook
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 3:31AM CDT
MedTech Defies Sequestration, M&As Steal the Show - Industry Outlook
MedTech Defies Sequestration, M&As Steal the Show - Investment Ideas
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 3:31AM CDT
MedTech Defies Sequestration, M&As Steal the Show - Investment Ideas
MedTech Defies Sequestration, M&As Steal the Show - Zacks Analyst Interviews
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 3:31AM CDT
MedTech Defies Sequestration, M&As Steal the Show - Zacks Analyst Interviews
Abbott Commences Tender Offer for All Outstanding Ordinary Shares and American Depositary Shares of CFR Pharmaceuticals S.A.
PR Newswire Europe - Mon Aug 25, 8:01AM CDT
Abbott today announced that its wholly-owned subsidiary, Abbott Laboratories (Chile) Holdco (Dos) SpA, a Chilean corporation ("ALH"
, has commenced a tender offer (the "U.S. Offer" , in which it is offering to purchase (i) from U.S. holders only, up to 100 percent of the outstanding ordinary, nominative, no par value shares (the "Ordinary Shares" of CFR Pharmaceuticals S.A. ("CFR" , a Chilean corporation and (ii) from all holders, wherever resident, up to 100 percent of the outstanding American Depositary Shares ("ADSs" issued pursuant to the Rule 144A Deposit Agreement or the Regulation S Deposit Agreement, each dated as of May 9, 2011, between CFR and The Bank of New York Mellon, as Depositary (the "ADS Depositary" , each of which represents 100 Ordinary Shares, in each case, on the terms and subject to the conditions set forth in the U.S. Offer to Purchase, dated Aug. 25, 2014, and in the related Ordinary Share Acceptance Letter and ADS Letter of Transmittal, as applicable.
Johnson & Johnson vs. Abbott Laboratories in the Battle for Emerging Market Turf
at The Street - Fri Aug 22, 3:55PM CDT
Emerging market pharmaceutical sales are exploding. Find out if Abbott Laboratories or Johnson & Johnson is best positioned to take advantage of the booming emerging market pharmaceutical market.
LABS, Inc. Names Todd G. Johnson as President and Chief Executive Officer
Business Wire - Tue Sep 02, 2:57PM CDT
LABS, Inc., a Centennial-based comprehensive, highly accredited specialized clinical reference testing laboratory, announced it has appointed Todd G. Johnson, MBA, as President and Chief Executive Officer. Based at LABS, Inc. Centennial headquarters, Johnson's initial priorities will be to continue to grow the company, and ensure that the organization remains competitive within the market place.
Next Support Level for Abbott Laboratories (ABT) is $41.89
Comtex SmarTrend(R) - Tue Sep 02, 12:28PM CDT
Shares of Abbott Laboratories (NYSE:ABT) opened today below their pivot of $42.24 and have already reached the first level of support at $42.06. Analysts will be watching for a cross of the next downside pivot targets of $41.89 and $41.54.
Fitch Maintains CFR's IDRs on Rating Watch Positive
Business Wire - Fri Aug 29, 12:47PM CDT
Fitch Ratings maintains CFR Pharmaceuticals S.A. and its subsidiary CFR International SpA on Rating Watch Positive in anticipation of their acquisition by Abbott Investments Luxembourg S.A.R.L., a subsidiary of Abbott Laboratories (Abbott; rated 'A+' by Fitch). A complete list of rating actions follows at the end of this press release.
Drug Discovery Technologies - A Global Market Overview
M2 - Fri Aug 29, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dtdx3f/drug_discovery) has announced the addition of the "Drug Discovery Technologies - A Global Market Overview" report to their offering. The development of new drugs for treating difficult diseases, such as cancer requires extensive expenditure, in addition to consuming a lot of time. The first step in designing a new drug involves the utilizing high-throughput screening of large chemical libraries for identifying compounds that can provide the requisite therapeutic effect. The capability of visualizing biological activity at the cellular level has constituted a strategic component in drug discovery, and adding automation and high-volume screening methods has enabled in testing compounds in large numbers. The field of pharmaceutical research is being provided considerable impetus through the combination of imaging and screening. Key Topics Covered: PART A: GLOBAL MARKET PERSPECTIVE 1. INTRODUCTION 2. KEY MARKET TRENDS 3. RECENT PATENTS IN DRUG DISCOVERY LANDSCAPE 4. KEY GLOBAL PLAYERS 5. KEY BUSINESS TRENDS 6. GLOBAL MARKET OVERVIEW PART B: REGIONAL MARKET PERSPECTIVE 1. THE UNITED STATES 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART C: GUIDE TO THE INDUSTRY 1. NORTH AMERICA 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART
ANNEXURE 1. RESEARCH METHOLOGY 2. FEEDBACK Companies Mentioned: - 4-Antibody AG - Abbott Laboratories - Accelrys, Inc. - Affymetrix Inc. - Agilent Technologies Inc. - Asahi Kasei Pharma Corporation - Astrazeneca Plc - Aviva Biosciences Corp. - Bayer Healthcare AG - BD Biosciences - Beckman Coulter Inc. - Biacore International AB - Bioanalytical Systems, Inc. - Bio-Rad Laboratories, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Caliper Life Sciences, Inc. - Caprion Proteomics, Inc. - Celera Corporation - Celgene Corporation - Charles River Laboratories International, Inc. - Compugen Ltd. - Decode Genetics, Inc. - EMD Millipore Corporation - Evotec AG - GE Healthcare Ltd. - Genedata AG - Hitgen Ltd - Hudson Robotics, Inc. - Illumina Inc. - Incyte Corporation - Isis Pharmaceuticals, Inc. - Kyowa Hakko Kirin Co., Ltd. - Luminex Corporation - Maxcyte, Inc - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Molecular Devices, LLC - Molecular Discovery Ltd. - Molecular Discovery Systems Pty., Ltd. - New England Biolabs, Inc. - Novartis AG - Osiris Therapeutics Inc. - Perkinelmer, Inc. - Promega Corporation - Qiagen N.V. - Quantum Pharmaceuticals - Roche Holding AG - Shimadzu Corporation - Sigma-Aldrich Corporation - Sri Biosciences - Tecan Group Ltd. - The National Center for Drug Screening - Thermo Fisher Scientific Inc. - Viva Biotech Ltd - Waters Corp. For more information visit http://www.researchandmarkets.com/research/dt..._discovery Global Infant Formula Market Report: Focus on China 2014
M2 - Thu Aug 28, 9:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/twqn7f/global_infant) has announced the addition of the "Global Infant Formula Market Report: Focus on China" report to their offering. The market for infant formula products is one of the major and the fastest growing segments of the overall baby foods industry. Infant formula is either a partial or a total substitute for breast milk for infants and is recommended for feeding during the first twelve months. Since the start of the millennium, international awareness regarding the importance of early childhood nutrition has been on the rise. All over the world parents are becoming more concerned about the nutritional benefit of pediatric foods and breast-milk supplements. Increasing proportion of women participation in labor force and increased affordability supported by waning price responsiveness and a rise in disposable income across the world are the major factors that have helped the global IMF market to attain stronger growth levels. Though the market has been experiencing lower demand and growth from the traditional matured markets of the West stemming primarily from declining birth rate, the developing world, especially the Asia and Pacific region and Latin America have provided the headroom for the global market expansion. The market is dominated by the Asian region which consumes about three-fifths of the global IMF supplies. Particularly, China has gained the stature to maneuver the market single-handedly since the country alone accounts for about two-fifth of the global IMF market revenues. The report, Global Infant Formula Market prudently analyzes the development of the respective market, with a focus on the single largest market, China, and other regional but important markets. The report discusses the major trends, growth drivers as well as issues being faced by the industry. The global infant formula market is predominated by a handful of players including Nestl?, Danone, Mead Johnson Nutrition and Abbott which keep vying for greater market share. The profiles of these leading players are also included in the report along with their key financials and strategies for growth. . Key Topics Covered: 1. Market Overview 2. Baby Food/Infant Nutrition Market 3. Market Dynamics 4. Competitive Landscape 5. Company Profiles 6. Market Outlook Companies Mentioned - Abbott Laboratories - Danone S.A. - Mead Johnson Nutrition Co. - Nestl? S.A. For more information visit http://www.researchandmarkets.com/research/tw...bal_infant
Frustrating Boston Scientific Is Not What the Investor Ordered
at The Street - Thu Aug 28, 5:30AM CDT
It will only take one bad quarter for shares to fall to single digits. That's the only time you should buy.
Abbott Laboratories Has Returned 10.4% Since SmarTrend Recommendation (ABT)
Comtex SmarTrend(R) - Wed Aug 27, 10:05AM CDT
SmarTrend identified an Uptrend for Abbott Laboratories (NYSE:ABT) on April 22nd, 2014 at $38.75. In approximately 4 months, Abbott Laboratories has returned 10.39% as of today's recent price of $42.77.
Home Healthcare Global Market Report - Forecast to 2020 for the $300 Million Industry
M2 - Wed Aug 27, 8:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lbsmjs/home_healthcare) has announced the addition of the "Home Healthcare Global Market - Forecast to 2020" report to their offering. Global home healthcare market is expected to reach more than $300 billion by 2019 growing at a CAGR of around 8.0% from 2014 to 2019 The home healthcare equipment market is expected to grow at a faster rate compared to home healthcare services market. Home healthcare is gaining a tremendous attention over hospitals for the sophistication, ease and privacy of treatment it offers. Increased in-hospital care cost, comfort of recovering at home and enhanced age-related chronic diseases in developing as well as developed countries are factors driving the overall growth of home healthcare market. Whereas factors such as poor technology adoption, weak reimbursement policies and rapidly changing technologies are hampering the market growth. Moreover, high capital costs, medical equipment, human resources and conventional model of business are the challenges faced by home healthcare market. The opportunities increasing the market trend is attributed to medical insurance by governments or organizations and cost-effectiveness.North America adopting novel technologies and portable diagnostic devices accounts for the largest share in the home healthcare market. While Europe with the presence of well-equipped healthcare reimbursement structure is the second leading market. Asia-Pacific is expected to grow at the highest CAGR driven by the aging population in countries such as India, China, and Japan. Key Topics Covered: 1. Executive Summary 2. Introduction 3. Market Analysis 4. Home Healthcare Therapeutic Equipment Market 5. Home Healthcare Services Market 6. Home Healthcare Telehealth Market 7. Regional Market Analysis 8. Company Developments 9. Major Company Profiles - Abbott Laboratories - Baxter International - Braun - Novo Nordisk - GE Healthcare - Invacare - Johnson and Johnson - Medtronic - Philips Healthcare - Roche Holding AG For more information visit http://www.researchandmarkets.com/research/lb...healthcare
Microfluidic Device System Market 2013 - 2019
M2 - Wed Aug 27, 3:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x345bg/microfluidic) has announced the addition of the "Microfluidic Device System Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. The global microfluidic device market was valued at USD 1,531.2 million in 2013. It is likely to grow at a CAGR of 22.8% during 2013 to 2019 to reach USD 5,246.4 million in 2019. Microfluidics is an evolving scientific field with numerous analytical applications and commercial potential. Globally, the microfluidic device market is witnessing significant growth due to increasing R&D investment in pharmaceuticals, life science and rising point of care testing demand. New trends in healthcare, such as healthcare at home, supports point of care testing (POCT) as the most efficient and effective delivery of healthcare. It has many applications in other areas such as drug screening, sugar testers, chemical micro reactor, microprocessor cooling and micro fuel cells. Rising demand for point of care testing, miniaturization of chip, and increasing demand for microfluidic devices in genomics and proteomics are the key growth drivers for the microfluidic device market. In addition, change in material mix would provide opportunity for new market entrants, which would further drive the growth of the microfluidic device market. North America was valued at USD 644.5 million in 2013 and is expected to reach USD 2,095.5 million in 2019, growing at a CAGR of 21.7% from 2013 to 2019. In-vitro diagnostics microfluidic device market was valued at USD 949.6 million in 2013 and is expected to reach USD 3,317.4 million in 2019, growing at a CAGR of 23.2% from 2013 to 2019. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Industry Analysis Chapter 4 Market Trends Chapter 5 Porters Five Force Analysis Chapter 6 Global Market Size and Forecast Chapter 7 Segment Analysis - by Material Chapter 8 Segment Analysis - by Industry Chapter 9 Segment Analysis - by Application Chapter 10 Regional Analysis Chapter 11 Competitive Landscape Chapter 12 Company Profiles - Abbott Laboratories - Agilent Technologies Inc - Becton, Dickinson and Company - Bio- Rad Laboratories - Cepheid - Dolomite Centre - Fluidigm Corporation - Johnson & Johnson - Micronit Microfluidics - RainDance Technologies - Roche Diagnostics - Siemens Healthcare For more information visit http://www.researchandmarkets.com/research/x3...crofluidic
Abbott Laboratories (ABT) Breaks Through Resistance at $42.70
Comtex SmarTrend(R) - Tue Aug 26, 10:41AM CDT
Shares of Abbott Laboratories (NYSE:ABT) have bullishly opened above the pivot of $42.49 today and have reached the first resistance level of $42.70. Should the shares continue to rise, the resistance pivots of $42.92 and $43.35 will be of interest.
Collaborations, New Contract, Dividend Declaration, and Capacity Expansion - Research Reports on Abbott, CB&I, Weyerhaeuser, Cardinal Health and SolarCity
PR Newswire - Tue Aug 26, 7:50AM CDT
Today, Analysts Review released its research reports regarding Abbott Laboratories (NYSE: ABT), Chicago Bridge & Iron Company N.V. (NYSE: CBI), Weyerhaeuser Co. (NYSE: WY), Cardinal Health, Inc. (NYSE: CAH) and SolarCity Corporation (NASDAQ: SCTY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5978-100free.
North American Interventional Cardiology & Peripheral Vascular Devices (Angioplasty Balloon, Stent, Catheter, IVC Filter, Endovascular Stent Graft) Market Report
M2 - Tue Aug 26, 3:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pxpdkk/north_american) has announced the addition of the "North American Interventional Cardiology & Peripheral Vascular Devices Market by Angioplasty Balloon, Stent, Catheter, IVC Filter, Endovascular Stent Graft - Forecast to 2018" report to their offering. The North American interventional cardiology and peripheral vascular devices market is expected to grow at a CAGR of 2.9% from 2013 to 2018. Both, the lower volume of coronary angioplasty procedures and the increasing prevalence rate of peripheral artery diseases have impacted the market significantly. Amongst all the product segments, bioabsorbable stents, retrievable inferior vena cava filters, and diagnostic catheters (intravascular ultrasound and optical coherence tomography catheters) markets are identified as the high growth segments in the North American interventional cardiology and peripheral vascular devices market. Better diagnosis of thrombus using IVUS and OCT catheters is expected to drive the diagnostic catheters market; whereas, lesser risk of long-term post surgical complications in DVT/PE treatments will encourage faster adoption of the retrievable inferior vena cava filters in the coming years. The bioabsorbable stents are still not available for clinical usage in the U.S. However, bioabsorbable stents are available on a special access basis by Health Canada. The usage factors of different surgical instruments were the major hindrances while deriving the market size of the corresponding surgical devices. This is primarily due to the availability of various surgical instruments for the treatment of similar cardiac ailments. For instance, coronary angioplasty can be performed through plain balloon catheter, stent, and/or a combination of stent and catheter, based on patients' cardiac health. The study on the North American interventional cardiology and peripheral vascular devices market captures an exhaustive list of surgical devices which are used in various types of angioplasty procedures, deep vein thrombosis, endovascular aneurysm repairing, and chronic total occlusion (CTO) treatment procedures. This research illustrates specific driving and restraining factors in the U.S. and Canadian markets; furthermore, it identifies the high-growth regions with regard to the interventional cardiology and peripheral vascular devices market. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Premium Insights 4 Market Overview 5 Angioplasty Balloons 6 Angioplasty Stents 7 Catheters Market 8 Endovascular Aneurysm Repair (EVAR) Stent Grafts Market 9 Inferior Vena Cava (IVC) Filters Market 10 Plaque Modification Devices Market 11 Hemodynamic Flow Alteration Devices Market 12 Accessory Devices Market 13 Geographic Analysis 14 Competitive Landscape 15 Company Profiles - Abbott Laboratories - Biotronik SE & Co. Kg - Boston Scientific Corporation - B. Braun Melsungen AG - Cook Medical, Inc. - Cordis Corporation - Covidien Plc - C. R. Bard, Inc. - Medtronic Inc. - W.L.Gore & Associates, Inc. For more information visit http://www.researchandmarkets.com/research/px...h_american
Nitinol Medical Devices Market Forecasts & Opportunities, 2019 - Semi-finished Raw Material & Final Medical Components Analysis
M2 - Tue Aug 26, 3:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w8xqrs/nitinol_medical) has announced the addition of the "Nitinol Medical Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. The total market of nitinol medical devices for final medical components was valued at USD 8,287.2 million in 2012 and is forecasted to grow at a CAGR of 11.1% during the period of 2013 to 2019. Based on the type of final medical components, the total market is subdivided into nitinol stents, guidewires and others, which comprises dental wires, catheter tubes, tissue ablators, needles, retrieval baskets, biopsy forceps, endodontic files and filters. Among these afore-mentioned components, nitinol stents market accounted for the largest market share in 2012 and is expected to retain its market share till 2019 due to increasing number of vascular stenting procedures globally. Additionally, growing medical device manufacturer's preference for using nitinol as a chief raw material owing to its unique biomechanical properties is further expected to drive the market for nitinol stents in coming years. Based on the type of semi-finished raw materials, the market is categorized into nitinol tubes, wiring and others, which comprise sheets and ribbons. The total market for nitinol semi-finished raw materials was valued at USD 1,525.2 million in 2012. Of these, the Nitinol-wiring market accounted for the largest market share in 2012. The contributing factors for such an assessment included a large number of clinical applications, low cost and better corrosion resistance properties compared to tubes and others. Nitinol wires are currently being deployed in various applications such as orthopedics, endoscopy, laparoscopy, catheter wall supports, ablation catheter, custom springs, etc. Geographically, North America constituted the largest market for global nitinol medical devices market in 2012; however, Asia-Pacific is predicted to foresee the fastest growth rate during the forecast period from 2013 to 2019. This high growth has been attributed to presence of large population base which consequently gives rise to large patient population, low treatment cost and increasing healthcare awareness among the patients. In addition, favorable government support and growing medical tourism industry would trigger the growth of this market in Asia-Pacific. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Nitinol Medical Devices Market, by Semi-finished Raw Material Chapter 5 Global Nitinol Medical Devices Market, by Final Medical Components Chapter 6 Global Nitinol Medical Devices Market, by Geography Chapter 7 Recommendations Chapter 8 Company Profiles - Abbott Laboratories, Inc. - Boston Scientific Corporation - Cook Medical, Inc. - Covidien plc - C. R. Bard, Inc. - Custom Wire Technologies, Inc. - ENDOSMART GmbH - Medtronic, Inc. - Nitinol Devices & Components, Inc. - Terumo Corporation For more information visit http://www.researchandmarkets.com/research/w8...ol_medical
MedTech Defies Sequestration, M&As Steal the Show - Industry Outlook
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 3:31AM CDT
MedTech Defies Sequestration, M&As Steal the Show - Industry Outlook
MedTech Defies Sequestration, M&As Steal the Show - Investment Ideas
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 3:31AM CDT
MedTech Defies Sequestration, M&As Steal the Show - Investment Ideas
MedTech Defies Sequestration, M&As Steal the Show - Zacks Analyst Interviews
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 3:31AM CDT
MedTech Defies Sequestration, M&As Steal the Show - Zacks Analyst Interviews
Abbott Commences Tender Offer for All Outstanding Ordinary Shares and American Depositary Shares of CFR Pharmaceuticals S.A.
PR Newswire Europe - Mon Aug 25, 8:01AM CDT
Abbott today announced that its wholly-owned subsidiary, Abbott Laboratories (Chile) Holdco (Dos) SpA, a Chilean corporation ("ALH"
, has commenced a tender offer (the "U.S. Offer" , in which it is offering to purchase (i) from U.S. holders only, up to 100 percent of the outstanding ordinary, nominative, no par value shares (the "Ordinary Shares" of CFR Pharmaceuticals S.A. ("CFR" , a Chilean corporation and (ii) from all holders, wherever resident, up to 100 percent of the outstanding American Depositary Shares ("ADSs" issued pursuant to the Rule 144A Deposit Agreement or the Regulation S Deposit Agreement, each dated as of May 9, 2011, between CFR and The Bank of New York Mellon, as Depositary (the "ADS Depositary" , each of which represents 100 Ordinary Shares, in each case, on the terms and subject to the conditions set forth in the U.S. Offer to Purchase, dated Aug. 25, 2014, and in the related Ordinary Share Acceptance Letter and ADS Letter of Transmittal, as applicable. Johnson & Johnson vs. Abbott Laboratories in the Battle for Emerging Market Turf
at The Street - Fri Aug 22, 3:55PM CDT
Emerging market pharmaceutical sales are exploding. Find out if Abbott Laboratories or Johnson & Johnson is best positioned to take advantage of the booming emerging market pharmaceutical market.
